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alternative approach to restore liver mass and function. Recent
progress has been reported on the generation of induced plurip-
otent stem (iPS) cells from somatic cells. Human-iPS cells can be
differentiated towards the hepatic lineage which presents possi-
bilities for improving research on diseases, drug development,
tissue engineering, the development of bio-artiﬁcial livers, and
a foundation for producing autologous cell therapies that would
avoid immune rejection and enable correction of gene defects
prior to cell transplantation. This focused review will discuss
how human iPS cell advances are likely to have an impact on
hepatology.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Allogeneic liver transplantation is the only effective treatment
available to patients with liver failure [84]. A serious shortage
of liver donors in combination with the high risk of organ rejec-
tion mandates alternative therapeutic approaches. Moreover,
operative damage and, in some cases, recurrence of pre-trans-
plant diseases can be considered as additional obstacles [72].
The discovery of human embryonic stem (ES) cells [136] has
raised the hopes for curing diseases that have poor prognoses.
However, after more than a decade of research, several challenges
related to ES cell safety, efﬁcacy, and bioethics have not been suf-
ﬁciently answered. For example, in 2009 the US Food and Drug
Administration (FDA) approved a clinical trial of human ES cell-
derived oligodendrocyte progenitors in spinal cord injury
patients, but it was subsequently placed on hold pending further
data regarding safety issues [50].
In a groundbreaking 2006 report, Yamanaka and co-workers
surprised the scientiﬁc community when they demonstrated thatJournal of Hepatology 20
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Baharvand).be reprogrammed into a pluripotent state similar to that observed
inES cells [134]. Thiswasachievedby the retroviral transductionof
Oct4, Sox2, Klf4, and c-Myc genes. These reprogrammed cells were
named induced pluripotent stem (iPS) cells. Subsequently
Yamanaka’s and Thomson’s laboratories successfully repro-
grammed human somatic cells into iPS cells [133,153]. Human-
iPS cells have the hallmarks of ES cell attributes including:
morphology, unlimited self-renewal, expressionof keypluripoten-
cy genes, and a normal karyotype. Additionally, in human-iPS cells
proof of functional differentiation into specialized cell lineages
of all three embryonic germ layers [57,118,122,130,154,155]
have been demonstrated. This wide differentiation potential pro-
vides fascinating possibilities and tools for the study of human
development and genetic diseases, in addition to their use for drug
discovery and regenerative medicine (reviewed in Ref. [95])
(Fig. 1).
In this review, we discuss the potentials of human-iPS cells
and challenges of using these cells in hepatology.Methods used for differentiation and enrichment of
hepatocyte-like cells from human ES and iPS cells in vitro
The directed differentiation of human ES cells (iPS cell coun-
terparts) into hepatocytes was ﬁrst reported in 2003 when
Rambhatla et al. used sodium butyrate to generate cells that
could express hepatocyte markers [103]. Subsequent reports
optimized this method and directed differentiation was
achieved in human ES cells by the administration of various
growth factors in a time dependent manner (Table 1). For
example, it was shown that Activin A and Wnt3a synergisti-
cally elicit rapid and highly efﬁcient differentiation of human
ES cells into functional hepatic endoderm [44]. Recently, Bas-
ma et al. presented a simple and reproducible growth factor-
mediated method to generate functional hepatocyte-like cells
(HLCs) from human ES cells [9]. Transplantation of HLCs
which were enriched based on asialoglycoprotein-receptor
(ASGPR) expression improved the liver mouse model [9]. In
addition to growth factors, a variety of protocols have been
used for the differentiation of human ES cells towards the
hepatic lineage; EB formation, co-culturing with hepatic and
non-hepatic cell types, genetic manipulation, and epigenetic10 vol. 53 j 738–751
Fig. 1. Progress towards safer iPS cells and application of differentiated hepatocytes.Methods have evolved from conventional viral integration to virus-free strategies
by transgene removal or the avoidance of viral integration. iPS cells have ﬁrst been generated using integrating retroviral and lentiviral vectors to deliver reprogramming
factors such as: OCT4, SOX2, KLF4, and c-MYC (A). Alternatively, iPS cells can be produced by the integration of reprogramming factors using the LoxP site containing
plasmids, lentiviruses, or piggyBac transposon mediated gene transfer system followed by removal of transgene sequences from the host genome using Cre or transposase
enzymes (B). Another strategy to generate iPS cells without viral integration used non-integrating viruses or plasmids to introduce reprogramming factors (C). Mouse and
human iPS cell lines were also derived using vector or adenoviruses that transiently expressed Oct4, Sox2, Klf4, and c-Myc (C). It was also shown that virus-free mouse iPS
cells could be generated using repeated plasmid transfections and by nucleofection of a single plasmid construct expressing Oct4, Sox2, Klf4, and c-Myc as a single
polycistronic unit (C). Human-iPS cells were also recently generated completely free of vector and transgene sequences by transfection of a non-integrating episomal vector.
Another recent strategy to create iPSCs without viral integration has been reported by protein transduction of the four reprogramming proteins fused with a cell-
penetrating peptide (CPP) (D). Somatic or iPS cells can be used to treat disease by correction of the underlying genetic defect. The wild-type gene can be used to replace the
defective gene by homologous recombination of somatic cells or iPS cells. The differentiated hepatic cell lineages provide fascinating possibilities and tools for the study of
disease models, tissue engineering, and creation of bio-artiﬁcial livers, in addition to their use for drug discovery and regenerative medicine.
JOURNAL OF HEPATOLOGYmodiﬁcations (Table 1). Moreover, the application of small
molecules has been used for the endodermal differentiation
from ES cells [12]. It has been demonstrated that these mole-Journal of Hepatology 201cules can regulate speciﬁc target(s) in signaling and epigenetic
mechanisms and can manipulate cell fate without genetic
alterations [69,110,147].0 vol. 53 j 738–751 739
Table 1. Differentiation protocols that direct human ES and iPS cells toward hepatocytes.
Differentiation protocol Hepatic features Major result(s) Ref.
Human ES cells
Stage 1 (4 days): EB formation, NaBu (5 mM)
or DMSO (1%), plated on Matrigel coated
plate; Stage 2 (10–11 days): DMSO (1%)
(4 days), NaBu (2.5 mM) (6–7 days); Stage 3
(4 days): NaBu (2.5 mM), HGF (2.5 ng/ml)
RT-PCR analysis of AFP, ALB, AAT, HNF4,
AGPR, GATA4, TAT, C/EBPa, C/EBPb; IF
analysis of ALB, AAT, AFP, CK8, CK18, CK19.
PAS staining, EROD assay, BrdU
incorporation
The ﬁrst report on differentiation of
human ES cells into functional HLCs
[103]
Stage 1 (20 days): EB formation and culture
in mouse primary hepatocyte CM; Stage 2
(10 days): Plated EB with or without GF
including aFGF (100 ng/ml), bFGF (5 ng/ml),
HGF (20 ng/ml), BMP4 (50 ng/ml)
RT-PCR analysis of AFP, apolipoprotein
(A4,B,H,F), ﬁbrinogen a,b,c, ALB, ADH1C;
FACS analysis of ALB-GFP
The ﬁrst report to demonstrate the
possibility of purifying
differentiated HLCs by genetic
manipulation with further culturing
[67]
Stage 1 (6 days): EB formation followed by
plating on collagen I; Stage 2 (8–43 days):
HGF (20 ng/ml), NGF (100 ng/ml), EGF
(100 ng/ml), aFGF (100 ng/ml), bFGF
(100 ng/ml), RA (1 lM), OSM (10 ng/ml),
bovine insulin (0.126 U/ml), Dex (100 nmol),
human insulin (0.126 U/ml)
qRT-PCR analysis of ALB, AAT; IF analysis
of ALB, Western blot analysis of ALB; urea
synthesis
The initial protocol for the
differentiation of HLCs
[116]
Stage 1 (7–14 days): EB formation followed
by plating on collagen 1 or either
ﬁbronectin, laminin, Matrigel, or uncoated;
Stage 2: Serum-free media with or without
HGF, OSM, aFGF, FGF7. (The time and
concentrations were not available)
qRT-PCR analysis of AFP, ALB, CK18, HNF3b,
HNF1, CK19, GATA4, CYP1A1, CYP1A2,
CYP2B6, CYP3A4, ASGPR1; IF analysis of
ALB, CK18, HNF3B, HNF1, immunoblot
analysis of ALB, CK18, HNF1, ASGPR1; urea
production, ICG uptake, CYP activity
Matrigel and collagen I had
greater inﬂuence on HLC differentiation
compared to laminin and ﬁbronectin
[111]
Stage 1 (5 days): EB formation; Stage 2 (20
days): Plated on collagen I or 3D collagen
scaffold, aFGF (100 ng/ml), HGF (20 ng/ml),
OSM (10 ng/ml), Dex (0.1 lM), ITS
RT-PCR analysis of HNF3b, AFP, TTR, AAT,
CK8, CK18, CK19, ALB, CYP7A1, TDO, TAT,
G6P; IF analysis of ALB, CK18; AFP & ALB
production, urea synthesis, ALB
production, EM (ultra structure
characteristics), PAS staining, ICG uptake
3D differentiation into HLCs made
more functional hepatocytes compared
to 2D cultures
[7]
Stage 1 (7 days): DMSO (1%); Stage 2 (9
days): HGF (2.5 or 10 ng/ml). Stage 3 (4
days): HGF (10 ng/ml), OSM (10 ng/ml)
RT-PCR analysis of AFP, TTR, HNF4a, AAT,
ALB, TDO, C/EBPa, hTERT; IF analysis of AFP,
HNF4a, ALB, HepPar1; Western blot
analysis of Sox7, Sox17, c-Met, E-cad; ICG
uptake, PAS staining, ELISA (ALB, AFP),
HPLC: CYP3A4 activity
HGF promotes HLC differentiation
in a dosedependent manner
[46]
Stage 1 (9 days): EB formation; Stage 2
(10–14 days): Plated on collagen I, IMDM,
FBS (20%), Dex (100 nM). Stage 3 (7 days):
Transduction with AAT-GFP lentivirus. Stage
4: GFP positive cell sorting
RT-PCR analysis of ALB, AAT, TF, AFP,
CYP1B1, CYP1A1, CYP2B6, CYP3A4, CYP2C9,
CYP2E1, ARG, G6P, HNF3|3, HNF4, C/EBPa, C/
EBPb, BMP2, BMP4, GATA4; IF analysis of
ALB, AAT, AFP, CK18; PAS staining, ICG
uptake, ALB production, transplantation,
ELISA (human ALB in mouse blood)
The ﬁrst to perform a successful
transplantation of bioluminescence
and GFP positive HLCs, to track their
fate in the animal liver, and detect
human serum albumin in an animal model
[27]
Stage 1 (3 days): Activin A (100 ng/ml) + 0%
ITS (1 day), Activin A (100 ng/ml) + 0.1% ITS
(1 day), Activin A (100 ng/ml) + 1% ITS
(1 day); Stage 2 (8 days): FGF4 (30 ng/
ml) + BMP2 (20 ng/ml). Stage 3 (5 days):
HGF (20 ng/ml). Stage 4: OSM (10 ng/ml),
Dex (0.1 lM)
RT-PCR analysis of AFP, ALB, CK8, CK18,
AAT, HNF4a, PEPCK, TDO, TAT, CYP7A1,
CYP2B6, CYP3A4, G6P, qRT-PCR analysis of
ALB; IF analysis of Sox17, FoxA2, CK7, CK8,
CK18, CK19, Ki67, AAT, ALB, AFP. ALB
production, LDL-uptake, PAS staining, ICG
uptake, PROD assay, animal model
transplantation, virus assay
The ﬁrst report testing the
susceptibility of HLCs by HCV
pseudovirus
[16]
Stage 1 (5 days): Activin A (100 ng/ml), 0.5%
FBS (3 days), Activin A (100 ng/ml), 2% FBS
or KOSR (2 days); Stage 2 (6 days): plated on
Collagen I-coated plate, FGF4 (1 0 ng/
ml),and HGF (10 ng/ml) (3 days), FGF4
(10 ng/ml), HGF (10 ng/ml), MDBK-MM, BSA
(0.5 mg/ml) (3 days); Stage 3 (9 days): FGF4
(10 ng/ml), HGF (10 ng/ml), OSM (10 ng/ml),
Dex (0.1 lM) (9 days)
RT-PCR analysis of AFP, ALB, AAT, CYP3A4,
CYP7A1. IF analysis of Sox17, FOXA2,
GATA4, Sox7, AFP, ALB, CD26, AAT, HNF4A,
Immunoblot analysis of Sox17, FOXA2,
GATA4, AFP. FACS analysis of CXCR4. ICG
uptake, PAS staining, ALB production,
animal model transplantation
Highly puriﬁed HLCs (70% ALB-
positive cells). Transplantation and
homing of DE into a mouse model
were demonstrated
[3]
Line missing
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Table 1 (continued)
Differentiation protocol Hepatic features Major result(s) Ref.
Stage 1 (3 days): NaBu (1 mM), Activin A
(100 ng/ml) (1–2 days), NaBu (0.5 mM),
Activin A (100 ng/ml) (2–3 days); Stage 2 (7
days): DMSO (1%); Stage 3 (7 days): HGF
(10 ng/ml), OSM (20 ng/ml), L15, FBS (8.3%)
RT-PCR analysis of Nanog, hTERT, Brachy,
GSC, Sox17, FoxA2, HNF4a, AFP, ALB, TAT,
TTR, TDO, CAR, ApoF, PAX6, CXCR4, HNF1a,
HNF1b, HNF6, CK7, CK18, CK19, Cyp3A4,
CYP3A7, CYP2C19, PXR; IF analysis of
FoxA2, HNF4a, AFP, ALB, HepPar, CK18,
CK19, CD13, CYP3A, CPR, c-Met. ﬂow
cytometry analysis of CXCR4, Western blot
analysis of FoxA2, HNF4a, AFP, ALB, AAT, c-
Met, E-cad, CYP3A, CYP2D6; Plasma
proteins: ﬁbrinogen, ﬁbronectin, A2M; PAS
staining, CYP activity measurement
Reporting of basal metabolism
activity and export proteins (alpha
2-macroglobulin, ﬁbrinogen, and
ﬁbronectin) by HLCs
[45]
Stage 1 (7 days): aFGF (100 ng/ml), FGF4
(10 ng/ml); Stage 2 (7 days): HGF (20 ng/
ml), FGF4 (10 ng/ml); Stage 3: HGF (20 ng/
ml), OSM (10 ng/ml), Dex (0.1 lM), ITS
RT-PCR analysis of Nanog, HNF3b, HNF4b,
C/EBPa, C/EBPb, CK8, CK18, CK19, TTR, AFP,
APOB, AAT, ALB, TDO, TAT, G6P, CYP7A1, IF
analysis of ALB, CK18, HepPar1; ﬂow
cytometry analysis of ALB, CK18; urea, ALB
& AFP production, PAS staining, ICG
uptake, LDL-uptake, TEM
Differentiation into functional HLCs
in a serum-free adherent culture
condition
[8]
Stage 1 (2 days): EB formation; Stage 2 (3
days): Plated on 5% Matrigel-growth factor
reduced, Activin A (100 ng/ml), bFGF
(100 ng/ml); Stage 3 (8 days): DMSO (1%),
HGF (100 ng/ml); Stage 4: Dex (0.1 lM)
qRT-PCR analysis of Nanog, SOX17, SOX7,
ALB, AFP, CFV||, ASGR1, PDX1, Nestin,
Brachury, Pax6, Nkx 2-5, G6P, UGT, oTc,
BSEP; IF analysis of ALB, AFP, FACS analysis
of ASGPR, immunohistochemistry analysis
of AAT, ALB; AAT & ALB production, animal
model transplantation, EM, CYP activity,
urea synthesis
A simple and reproducible protocol
for establishing functional
HLCs and transplantation of
ASGPR1 – enriched cells into Alb-uPA
SCID mice
[9]
Stage 1 (2 days): EB formation; Stage 2 (3
days): Activin A (100 ng/ml), 1% FBS (in
suspension). Stage 3 (5 days): Plated on
irradiated feeder cells secreting bFGF in
HepatoZYME medium; Stage 4 (6 days):
HGF (20 ng/ml), OSM (10 ng/ml), Dex
(0.1 lM)
RT-PCR analysis of Sox17, AFP, bFGF, ALB,
CK18, CYP1B1; IF analysis of Sox17, ALB,
AFP; ICG uptake and release, PAS staining,
ALB production, EM
Induction to the early lineage stage of
hepatic fate by co-culturing activin-derived
endoderm with feeder cells that secreted
bFGF
[102]
Stage 1 (3 days): Activin A (100 ng/ml) + 0%
ITS. (1 day), Activin A (100 ng/ml) + 0.1% ITS
(1 day), Activin A (100 ng/ml) + 1% ITS
(1 day); Stage 2 (5 days): FGF4 (30 ng/
ml) + BMP2 (20 ng/ml); Stage 3 (5 days): N-
CAD+ cell sorting, plated on STO feeder, HGF
(20 ng/ml); Stage 4 (5 days): OSM (10 ng/
ml), Dex (0.1 lM)
RT-PCR analysis of AFP, CK8, CK18, ALB,
AAT, TAT, CYP2B6, CYP3A7, PEPCK, CK7; IF
analysis of AFP, N-CAD, ALB, HNF4A, GATA4,
FOXA2, AAT, CK7; ALB secretion, PAS
staining, ICG uptake, LDL uptake, PROD
assay
The ﬁrst proliferative bipotential
hepatic progenitor cells that have
been reported by sorting N-CAD+
cells
[156]
Stage 1: ES cells plated on ﬁbronectin or FBS
coated plate, Activin A (10 ng/ml), bFGF
(12 ng/ml); Stage 2 (3 days): Ly294002
(1 lM), Activin A (100 ng/ml), BMP4 (10 ng/
ml), bFGF (20 ng/ml); Stage 3 (5 days):
FGF10 (50 ng/ml) (3 days), FGF10 (50 ng/
ml), RA (0.1 lM), SB431542 (1 uM) (2 days);
Stage 4 (10 days): HGF (50 ng/ml), FGF4
(30 ng/ml), EGF (50 ng/ml)
RT-PCR analysis of Bra, MixL1, Sox17, Sox7,
Lhx1, GATA6, CXCR4, Eomes, Hex,
microarray analysis; IF analysis of Sox17,
FoxA2, GATA4, N-cad, AAT, ALB, CK8, CK18;
ﬂow cytometry analysis of CXCR4, ASGPR,
LDLR, c-met, CD49f; albumin secretion,
CYP activity, PAS staining, LDL uptake, ICG
uptake, animal transplantation
Combination of high dosages of Activin,
BMP4, bFGF in addition to PI3K inhibitor,
Ly294002, lead to a more efﬁcient DE. HLC
transplantation in a mouse model with
transient block of liver growth, thus
allowing for better engraftment of the
transplanted cells
[139]
Stage 1 (1-5 days): Activin A (100 ng/ml),
bFGF (4 ng/ml) or Wnt3a (50 ng/ml). FBS
concentration 0% ﬁrst day, 0.2% following
days; Stage 2 (6–17 days): BMP4 (100 ng/
ml), bFGF (4 ng/ml). Some experiments:
aFGF (100 ng/ml), bFGF (5 ng/ml), BMP2
(50 ng/ml), BMP4 (200 ng/ml); Stage 3: Dex
(0.1 lM), OSM (10 ng/ml), HGF (20 ng/ml),
singleQuots (Lonza)
RT-PCR analysis of Sox17, HNF3b, CXCR4,
AFP, AAT; IF analysis of ALB, AAT, AFP, CK7,
CK8, CK18, Ck19. CXCR4, CYP1A2, CYP3A4,
EpCAM, HNF3b, HNF1a, HNF4a, Sox7,
ICAM1, MRP2, Sox17, LFABP, Western blot
analysis of AAT, AFP, CYP3A, MRP2, OATP2;
ICG uptake, urea production, PAS staining,
CYP activity (Midazelam, Diclofenac,
Phenacetin)
A more realistic DE by a
combination of Activin A
and bFGF (excluding extra-embryonic
endoderm)
[13]
Line missing (continued on next page)
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Table 1 (continued)
Differentiation protocol Hepatic features Major result(s) Ref.
Stage 1 (3 days): Activin A (100 ng/ml)
(2 days), Activin A (100 ng/ml), B27, NaBu
(0.5 mM); Stage 2 (11–15 days): Splitting
cells in collagen I-coated plate or non-
splitting cells, FGF4 (20 ng/ml), HGF (20 ng/
ml), BMP2 (10 ng/ml), BMP4 (10 ng/ml)
(1 day). The same supplement, DMSO 0.5%
(10–14 days); Stage 3: FGF4 (20 ng/ml), HGF
(20 ng/ml), OSM (50 ng/ml), Dex (100 nM),
0.5% DMSO
RT-PCR analyses of CYP1A 1, CYP1B1,
CYP2A6, CYP2A7, CYP2B6, CYP2C8,
CYP2C19, CYP2B1, CYP7A1, UGT1A3,
UGT1A6, UGT1A8, UGT1A10 and IF analyses
of CXCR4, SOX17, FOXA2, ALB, AAT, AFP,
ASGPR, nuclear receptor, nuclear
transporter, MRP1, OATP2, AhR, CAR, PXR,
CPR, LXR; ﬂow cytometry analysis of
CXCR4, SOX17, FOXA2, AFP, ALB, AAT,
ASGPR; Western blot analysis of CYP1A2,
CYP3A4, CYP2C9, CYP2D6, UGT1A1, UGT2B7,
GST P1-1, GST A1-1; albumin secretion, ICG
uptake, metabolic activity, drug
metabolism
Homogenous population of HLCs
(90% albumin positive, 60% ASGPR
positive, and 70% AAT positive)
which indicates comparable
functionality to primary hepatocytes
[28]
Human-iPS cells
Stage 1 (3 days): Activin A (100 ng/ml);
Stage 2 (4 days): FGF4 (30 ng/ml), BMP2
(20 ng/ml); Stage 3 (6 days): HGF (20 ng/
ml), KGF (20 ng/ml); Stage 4 (6 days): OSM
(20 ng/ml), Dex (0.1 lM). Stage 5 (3 days):
OSM (20 ng/ml), Dex (0.1 lM), N2, B27
RT-PCR analysis of AFP, Alb, CK8, CK18,
CK19, PEPCK, HNF4a, HNF6, CEBPa, GATA4,
HEX; IF analysis of Sox17, Sox7, CDX2,
Foxa2, ALB, AFP, AAT, CYP7A4; urea
synthesis, PAS staining, ELISA: ALB
production, CYP45: inductive activity by
drug
Hepatoblast expansion step by KGF
and FGF10
[122]
Stage 1 (5 days): Activin A (100 ng/ml),
Wnt3 (25 ng/ml) (3 days), Activin A (100 ng/
ml) (2 days); Stage 2: DMSO 1%; Stage 3: L15
medium, tryptose phosphate broth (8.3%),
FBS (8.3%), hydrocortisone (10 lM), insulin
(1 lM), HGF (10 ng/ml), OSM (20 ng/ml)
RT-PCR analysis of AFP, Cyp7A1, HNF4a,
Cyp1A2, Cyp3A4; IF analysis of albumin, E-
cadherin, ELISA: AFP, TTR, ﬁbrinogen,
ﬁbronectin; CYP activity: CYP1A2, CYP3A4
The ﬁrst report on the generation of
functional HLCs from human-iPS
cells
[130]
Stage 1 (5 days): Activin A (100 ng/ml);
Stage 2 (5 days): bFGF (10 ng/ml), BMP4
(20 ng/ml); Stage 3 (5 days): HGF (20 ng/
ml); Stage 4 (5 days): OSM (20 ng/ml)
Oligonucleotide array analysis; IF analysis
of FOXA2, SOX17, GATA4, FOXA2, HNF4a,
AFP, ALB; ﬂow cytometry analysis of ALB;
PAS staining, ICG uptake, LDL uptake, urea
synthesis
Transplantation of HLCs into the
lobe of newborn mice and with
demonstration of homing
[118]
This protocol was similar to [139] qRT-PCR analysis of HNF4a, AFP, ALB; IF
analysis of HNF4a, AFP, CK8, CK18
Hepatic lineage differentiation
protocol for ES cells that generated
HLCs from iPS cells
[139]
Stage 1 (5 days): Activin A (100 ng/ml), 0.5%
FBS or 1% KOSR; Stage 2 (10 days):
trypsinized and plated on collagen I-coated
plate, FGF4 (10 ng/ml), HGF (10 ng/ml)
(2 days), minimal Madin–Darby bovine
kidney maintenance medium, FGF4 (10 ng/
ml), HGF (10 ng/ml); Stage 3 (10 days):
SingleQuotes (lonza), FGF4 (10 ng/ml), HGF
(10 ng/ml), OSM (10 ng/ml), Dex (0.1 lM)
Flow cytometry analysis of CXCR4; IF
analysis of AFP, ALB, AAT, CYP3A4; PAS
staining; CYP activity: CYP1A2, CYP3A4
Generation of HLCs from
hepatocyte-derived iPSc
[71]
a2M: alpha-2-Macroglobulin, AAT: Alpha-1-Antitrypsin, aFGF: acidic Fibroblast Growth Factor, AFP: Alpha Feto Protein, AGPR: Aasialo Glyco Protein receptors, ADH1C:
Alcohol dehydrogenase 1C, ALB: Albumin, APOB: Apolipoprotein B, ARG: Arginase, bFGF: basic ﬁbroblast growth factor, BrdU: Bromo deoxyuridine, BSEP: Bile salt export
pump, BMP: Bone morphogenetic protein, C/EBP: CCAAT enhance binding protein, CM: Conditioned media, CAR: Constitutive androstane receptor, CF VII: Coagulation
Factor VII, CK: Cytokeratin, CM: Conditioned media, c-Met: Mesenchymal-epithelial transition factor, CPR: Cytochrome P450 reductase, DE: Deﬁnitive endoderm, DEX:
Dexamethasone, DMSO: Dimethyl sulfoxide, EB: Embryoid body, E-cad: E-cadherin, EGF: Epidermal growth factor, ELISA: Enzyme linked immunosorbent assay, EM:
Electron microscopy, EROD: Ethoxyresoruﬁn-O-deethylase, FACS: Flow cytometry activated cell sorting, FBS: Fetal bovine serum, FGF4: Fibroblast growth factor, GF:
Growth factor, G6p: Glucose 6-phosphatase, GFP: Green ﬂuorescence protein, GSC: Goosecoid, HGF: Hepatocyte growth factor, HLC: Hepatocyte-like cell, HNF: Hepatocyte
nuclear factor, ICG: Indocyanin green, IF: Immuno ﬂuorescence, ITS: Insulin/transferrin/selenium, KGF: Keratinocyte growth factor, Ly294002: PI3 kinase inhibitor, N-CAD:
N-cadherin, NGF: Nerve growth factor, NaBu: Sodium butyrate, OTC: Ornithine transcarbamylase, OSM: OncostatinM, PAS: Periodic acid-Schiff, PEPCK: Phospho enol
pyruvate carboxykinase, PROD: Pentoxyresoruﬁn, RA: Retinoc acid, SB431542: TGF-beta inhibitor, TAT: Tyrosine amino transferase, TDO: Tryptophan-2,3-dioxygenase,
TEM: Transmission electron microscopy, TERT: Telomerase reverse transcriptase, TF: Transferin, TTR: Transthyretin, UGT: Bilirubin-UDP glucuronosyl transferase.
ReviewIt was shown that HLCs could also be generated from human-
iPS cells [71,118,122,130,139] (Table 1), demonstrating the efﬁ-
cacy of these approacheswith pluripotent stem cells of diverse ori-
gins. Here, the term in vitro HLCs indicates some of the properties742 Journal of Hepatology 201of mature hepatocytes (Table 1). The characteristics of stem cell-
derived hepatocytes produced from various differentiation proto-
cols have been critically reviewed [47,107]. The differentiated cells
should be assessed by comparing themwith primary liver-derived0 vol. 53 j 738–751
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cells formorphology and the expression of a set of proteins such as
a-fetoprotein and albumin. However, ultimately, in vitro proof
that mature HLCs have been produced need demonstration of
functional hepatocyte properties such as nutrient processing,
detoxiﬁcation, plasma protein synthesis, and engraftment, after
transplantation into a suitable animal model [107].Human-iPS cells as disease models
The use of animal models is one of the established ways to study
themechanisms of liver diseases and possible therapeutic applica-
tions. Several genetic disorders which involve hepatocytes have
been modeled in rodents and large animals (Supplementary
Table 1). Although these models of human congenital and
acquired diseases are invaluable, they provide a limited represen-
tation of human pathophysiology. Animal models do not always
faithfully mimic human diseases, particularly those for human
contiguous gene syndromes. For example, mice carrying the same
genetic deﬁciencies as Fanconi’s anemia patients do not develop
spontaneous bone marrow failure which is the hallmark of the
human disease [19]. Huntington’s disease patients show dyskine-
sia (involuntary movements), whereas mice do not [106]. More-
over, many genetic diseases within the liver do not have hot
spots nor do they arise from mutations within a single gene. For
example, the gene for a-1 antitrypsin has been mapped on the
long arm of chromosome 14 and, to date, although as many as
100 alleles have been found for a-1 antitrypsin deﬁciency, only
a small number of them are associated with liver disease [32]. In
addition, it is difﬁcult to undertake genetic studies of human dis-
eases in animalmodels when the genes involved are unknown [4].
Researchers have tried to overcome these problems by using
humancell cultures alongwith animalmodels as essential comple-
ments to human disease studies. Primary human cells have a lim-
ited life span in culture. As a result, most human cell lines in wide
use today carry genetic and epigenetic artifacts which arise from
their accommodations to tissue cultures and are derived either
frommalignant tissues or have been genetically modiﬁed in order
to drive immortal growth [37]. Indeed, many human cell types
have never faithfully been adapted for growth in vitro. Human
embryos which have been shown to carry genetic diseases by vir-
tue of preimplantation genetic diagnoses canyield ES cell lines that
model single-gene disorders [142]. For example, human ES cell
lines have been generated for disorders such as cystic ﬁbrosis
[80], Huntington’s disease [80], and Fragile X syndrome [30]. How-
ever, the vastmajority of diseases that showmore complex genetic
patterns of inheritance are not represented in this pool.
The ability to create pluripotent stem cell lines from patients
exhibiting speciﬁc diseases may facilitate the construction of a
library of iPSCs. As such, disease-speciﬁc human-iPS cells provide
an unprecedented opportunity to recapitulate and investigate
human pathologies in vitro. Several groups have successfully
derived a wide range of iPS cells from patients with diseases
(for review see [112]). Therefore, it is possible to generate iPS
cells from patients who have inherited liver diseases. These cells
can be used as instruments to study the pathogenesis, disease
mechanism(s) and possible cures for inherited liver disorders.
However, the demonstration of disease-related phenotypes and
the ability to model pathogenesis and treatment of disease
remain key challenges in this ﬁeld. It should be noted that many
diseases might be non-autonomous with the involvement of
more than one cell type in the disease process. One possible solu-Journal of Hepatology 201tion would be the simultaneous culture of several cell types.
Another problem is the time frame which disease symptoms
are manifested. For example, amyotrophic lateral sclerosis (ALS)
or Parkinson’s disease (PD) symptoms may take years to develop.
Role of human-iPS cells in drug development and toxicity
evaluation
According to a report by the US Food and Drug Administration, ‘‘a
10-percent improvement in predicting failures before clinical tri-
als could save $100 million in development costs per drug.” [1].
Therefore, there is increasing demand for new in vitro models
to improve drug development by narrowing selected target drugs
or eliminating toxic and non-effective drugs during the ﬁrst
stages of development. A cell-based assay should be simple, fast,
reproducible, and cost effective with a consistent supply. Tradi-
tionally, whole embryo cultures and cells for drug research and
analysis have been derived from animal or human tissues; either
as primary cultures in which batch-to-batch variability is a com-
mon problem or as immortalized lines which often harbor
uncharacterized genetic abnormalities [124]. The mouse ES cell
test [14,99] is also one of the most recently developed tests used
to assess the embryotoxic potentials of test chemicals, however,
it may not entirely mimic human pharmacological risk assess-
ment due to differences in xenobiotic biotransformation path-
ways and capacities. Human ES cells can be utilized as in vitro
models for drug development and toxicology analyses, as well
[42,55]. Today approximately 70% of the top 20 pharmaceutical
companies utilize stem cells in their research and among these,
64% use human ES cells or their derivatives [22,43,45,55].
Although of value, human ES cells and their derivatives do not
encompass all the variances within a population or all ethnicities.
The generation of iPS cells from individuals will more faithfully
represent the highly polymorphic variants in metabolic genes
of human populations and provide the pharmaceutical industry
with a unique opportunity to revolutionize toxicological assays
[17,113,130]. In support of this, human iPS cell-derived cardio-
myocytes have recently been used to study the effect of cardioac-
tive drugs [135,151]. Moreover, Lee et al. have used neural
disease familial dysautonomia (FD)-iPS cells for validating the
potency of candidate drugs in reversing aberrant splicing and
ameliorating neuronal differentiation and migration of FD [68].
The liver is the primary organ involved in drugmetabolism and
therefore one of themost common tissues affected by drug toxicity
[45]. Although there are no current studies, iPS cell-derived hepa-
tocytes could soon replace hepatocytes or hepatoma cell lines in
drug toxicity screening assays [39,45]. Hepatocytes generated
from iPS cells that have been derived from individuals with differ-
ent cytochrome p450 polymorphisms would be of immense value
for predicting potential liver toxicities of new drugs in patients
[148]. Additionally, liver disease-speciﬁc iPS derived hepatocytes
can be utilized to discover the effects of new drugs on speciﬁc
disorders before proceeding to animal studies and clinical trials.
Human iPS cell-derived hepatocytes in a bio-artiﬁcial liver design
Extracorporeal bio-artiﬁcial liver (BAL) systems aim to bridge
patients until a suitable donor organ becomes available for whole
organ or cell transplantation, or liver regeneration. BAL systems
consist of viable hepatocytes in different perfusion bioreactor
conformations. The patient’s blood perfuses through one of these
systems, theoretically compensating for the liver’s vital functions.0 vol. 53 j 738–751 743
Review
Different BAL systems are currently undergoing clinical trials
[34,81,83,108,141]. Although these devices have bridged a num-
ber of patients to transplantation, [25,108,141] their efﬁciency
should be enhanced. Among the considerations that are neces-
sary for the development of BAL devices (for review see [100]),
the cellular component plays a critical role. To date, the different
cell types that have been used in various BALs include primary
porcine or human hepatocytes [101], cell lines [105], fetal liver
cells [87], and ES cell-derived cells [123]. Primary hepatocytes
often retain their differentiated functions for a short duration
in vitro. In addition, immunogenic reactions resulting from the
xenogenecity of porcine hepatocyte products and the possibility
of xenozoonotic retroviral infection of patients with porcine
endogenous retrovirus (PERV) [144] are major drawbacks to
using these cells. Primary human hepatocytes, on the other hand,
are not available in sufﬁcient amounts needed for clinical BAL
usage. Continuous cell lines, as the other cell source, often lose
functions that cells possess in vivo [97].
Human ES cells and iPS cells, however, show great promise as
cell sources for BAL devices. Self-renewal and the high potential
to differentiate into all cell types, including hepatocytes, make
them good candidates. Optimization of the current differentiation
protocols can allow these cells to substitute for presently used
cell sources.
Human-iPS cells and tissue engineering: founders of personalized
regenerative medicine
Tissue engineering approaches facilitate the pathway from
laboratory to clinic. The tissue engineering technique, which
mimics in vivo conditions, leads to maximum cellular function
in vitro [75] and eases the scale-up cultures which are impor-
tant for transplantation strategies or extracorporeal bio-artiﬁcial
livers.
Under monolayer culture conditions hepatocytes lose their
liver speciﬁc functions within a few days [21]. Therefore,
researchers have studied various extracellular matrix (ECM) com-
positions, scaffolds and bioreactor designs, such as galactosylated
polymers [20,149], spheroid cultures [137] and perfusion biore-
actors [24,117] to enhance primary hepatocyte function in vitro
[91,131]. Differentiation of human ES and iPS cells into hepato-
cytes in spheroid cultures [86] or in perfusion bioreactors and
culturing ES/iPS cell-derived HLCs onto galactosylated polymers
could one approach to enhance the yield and functionality of dif-
ferentiated cells. Additionally, tissue engineering may assist in
deriving more mature HLCs from ES and iPS cells within ratio-
nally tailored three-dimensional microenvironments [79] which
simulate the natural ECM and maintain mature, functional hepa-
tocytes [33]. In recent years, studies have demonstrated the
effects of different ECMs or bioreactor conﬁgurations on the
hepatic differentiation of ES cells [7,54,86], however additional
research should be undertaken to determine the optimum condi-
tions necessary for maturation of ES cell-derived hepatocytes.
The combination of tissue engineering with iPS cells as a per-
sonalized and easily expandable cell type shows great potential
for the treatment of multiple liver diseases. By using this
approach, hepatic induction of iPS cells would be the ﬁrst step
in personalized treatment for end stage liver diseases either
through cell therapy, BAL treatment, or by personalized drug
screening; all of which have been discussed in detail in this
review.744 Journal of Hepatology 201Human iPS cell transplantation for the treatment of liver
disease
Hepatocyte transplantation has recently been used as an alterna-
tive to orthotopic liver transplantation (OLT) in patients with
liver-based congenital metabolic disorders such as: alpha-1 anti-
trypsin deﬁciency [129], urea cycle defects [49,128], Crigler–Naj-
jar I [5,35,59], glycogenosis type Ia [89], Refsum disease
(heredopathia atactica polyneuritiformis), coagulation factor
deﬁciency [119], argininosuccinate-lyase deﬁciency [126], and
factor VII deﬁciency [26]. Promising results and partial correction
of disease symptoms have been obtained from most of these
studies [5,26,35,59,89,119,126]. However, the metabolic
improvement does not persist and therefore it is necessary to
repeat hepatocyte infusions [126,150].
The routine clinical deployment of cell transplantation is fur-
ther complicated by the scarcity of transplantable allogeneic
hepatocytes, their variable engraftment rates and the difﬁculty
in monitoring allograft rejection. Moreover, in vitro expansion
of mature hepatocytes is not feasible because long term cultiva-
tion of hepatocytes results in a reduction in hepatocyte
metabolism.
Although limited clinical success has been reportedwith bank-
ing cryopreserved hepatocytes [109,127], this may not alleviate
cell shortages since human hepatocytes are easily damaged dur-
ing the freeze-thaw procedure. Hence, there is a need for addi-
tional cell sources such as stem or progenitor cells that can be
expanded and differentiated into hepatocytes. Many studies have
shown the therapeutic potential of various stem cells (for review
see [29] and Supplementary Table 2). The iPS cells are merging
as the most promising source for the derivation of truly isogenic
grafts. Differentiated derivatives of iPS cells that ameliorate a
range of diseases in animal models have been reported. For
instance, human iPS cell-derived neural progenitors transplanted
into the brains of rats with PD generated functional dopamine
neurons [15] and human iPS cell-derived cardiomyocytes have
demonstrated in vivo functional integration in animals with
infarcted hearts [90]. Moreover, mouse iPS cells have been used
as sources for transplants to restore auditory spiral ganglion neu-
rons [96]. Transplantation of mouse iPS cell-derived endothelial
cells and endothelial progenitor cells into the livers of irradiated
hemophilia Amice have increased survival rates and plasma factor
VIII [146]. To date, there is no report on the transplantation of iPS
cell-derived hepatocytes into animal models, but successful dif-
ferentiation of human-iPS cells into hepatocytes [118,122,130]
has paved the way for the future application of patient-speciﬁc
iPS cells to be utilized as cell therapies for liver diseases.Human iPS cell therapies for hereditary metabolic liver
diseases
Cell therapy of hereditary liver diseases (Supplementary Table 3)
with patient-speciﬁc iPS cells would require ex vivo gene correc-
tion before (somatic cell) or after reprogramming (Fig. 1). There
are reports of successful gene therapies with different cell types,
including ES cells and hepatocytes, that can overcome genetic
disorders such as familial hypercholesterolemia, Gligler–Najjar,
hypercholestasis and albumin deﬁciency [53,63,66]. In a liver-
directed gene therapy study of patients with homozygous famil-
ial hypercholesterolemia, Grossman et al. [38] have demon-0 vol. 53 j 738–751
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strated the feasibility of engrafting limited numbers of retroviral-
transduced hepatocytes. In this study, the results have shown a
lack of toxicity and persistent gene expression lasting at least
four months following gene therapy. Successful reports of human
hepatocyte genetic correction, using lentiviral vectors, followed
by transplantation in the Gunn rat [94] [10,92] and nonhuman
primates [82] have been published. These ﬁndings conﬁrm the
potential feasibility of gene therapy by using lentiviral vectors
to treat liver-based inborn errors of metabolism, which are a pre-
requisite to clinical applications (for review see [93]).
Patient-speciﬁc iPS cells are considered a promising alterna-
tive for an ex vivo gene therapy approach. With this strategy,
mouse iPS cells have been successfully derived from a mouse
model of sickle cell anemia. The defective gene was replaced by
homologous recombination at the beta-globin locus prior to the
generation of hematopoietic stem cells. Treated iPS cells subse-
quently differentiated into hematopoietic precursors which have
been successfully used in the sickle cell mouse [41]. Raya et al.
corrected the genetic defect existent in somatic cells of Fanconi’s
anemia patients and generated iPS cells that have the potential to
differentiate into hematopoietic progenitors of phenotypically
normal disease-free myeloid and erythroid lineages [104]. These
data offer proof of concept that iPS cell technology can be used to
generate patient-speciﬁc cells with the potential value for cell
therapy applications and curing diseases.
Induced liver progenitor cells/hepatocytes
To generate iPS cells, somatic cells must ﬁrst be completely dedif-
ferentiated into pluripotent stem cells and then subsequently
redifferentiated into the adult cell type of interest; a time-con-
suming procedure that risks teratoma formation of pluripotent
stem cells. If the generation of either somatic stem or progenitor
cells, or fully differentiated cells directly from ﬁbroblasts or other
types of somatic cells could be achieved, it might not be neces-
sary to produce iPS cells and therefore the risk of teratoma forma-
tion would be eliminated. The reprogramming of mouse and
human ﬁbroblasts into iPS cells with a combination of repro-
gramming factors has raised the question of whether transcrip-
tion factors could directly induce other deﬁned somatic cell
fates. A remarkable breakthrough that addressed this question
was achieved when the transient activation of three transcription
factors (Ngn3, Pdx1, and Mafa) induced the direct reprogram-
ming of adult mouse pancreatic exocrine cells into insulin-pro-
ducing endocrine cells with robust (20%) efﬁciency [159].
Motoyama et al. showed reprogramming of adult hepatocytes
into insulin-producing cells by nucleofection of non-viral bisic-
tronic vectors including Pdx1 and Ngn3 [88]. However, in these
and most other studies, the reprogramming occurred only
between closely related cell lineages. Recently, Veirbuchen
et al. set out to determine whether speciﬁc transcription factors
could directly reprogram ﬁbroblasts into functional neurons
[143]. They began with a set of 19 candidate transcription factors
involved in neuronal development or function. Eventually a com-
bination of only three transcription factors (Ascl1, Brn2, and
Myt1l) that rapidly and efﬁciently converted mouse embryonic
and postnatal ﬁbroblasts into functional neurons in vitro was
discovered.
Although transdifferentiation may eventually replace current
technologies for generating iPS cells and ES cells, future studies
will be necessary to determine whether induced differentiatedJournal of Hepatology 201cells could represent an alternative method to generate patient-
speciﬁc hepatocytes.Challenges in the application of human-iPS cells for therapy
Although iPS technology offers multiple treatment opportunities,
substantial technical advances are necessary before clinical appli-
cations can be considered.
Collection and establishment of iPS cells under GMP guidelines
The starting cell material should be obtained and processed in
conditions that are acceptable under goodmanufacturing practice
(GMP) guidelines from rather young donors in order to avoid accu-
mulation of environmental DNA damage. A recent report indicates
that banked cord blood samples might offer a solution to this
problem and provide ‘‘naive” cells as starting material for the
future generation of clinical grade iPS cells [36,40]. Furthermore,
the maintenance, expansion, and differentiation of iPS cells will
require GMP compatible cell culture conditions which need to
avoid cells, chemicals and proteins that are from animal sources.
Recent reports have shown that iPS cells can be generated in
serum and feeder-free conditions and maintained in chemically
deﬁned and xenobiotic-free media and supplements [132,138].
However, whether there are physiological differences
between human-iPS cells established and grown under standard
conditions versus feeder- and serum-free conditions remains
unknown.
Generation of iPS cells without genetic modiﬁcations
One major challenge is to design methods that involve minimal
modiﬁcation to the genome and generate safer iPS cells for cell
therapy (for review see [112]). Virus-mediated delivery of repro-
gramming factors could result in potential harmful genomic
alterations. Several groups have reported the derivation of iPS
cells by integration of the four reprogramming factors with the
use of plasmids [56] and lentiviruses [120] followed by removing
transgene sequences from the host genome using Cre-lox medi-
ated excision (Fig. 1). The combination of a single-vector system
and piggyBac transposon has been utilized for reprogramming
mouse embryonic ﬁbroblasts which resulted in the seamless
elimination of vector and transgene sequences from iPS cells by
transposase re-expression [56,145] (Fig. 1).
Removal of the reprogramming vector increased the similarity
of iPS cells to ES cells [120] and markedly improved the develop-
mental potential and differentiation capacity of iPS cells [121].
iPS cells were also generated without viral integration by exploit-
ing non-integrating viruses or plasmids to introduce reprogram-
ming factors [98,125,152].
The protein transduction approach has been suggested as an
alternative to a nucleic acid-based approach for the reprogram-
ming of somatic cells into iPS cells without genetic manipulation.
It has been demonstrated that protein transduction domains, also
called transduction peptides or cell-penetrating peptides (CPP),
allow the cargo protein to enter the cell when fused to them.
The generation of stable iPS cells frommouse ﬁbroblasts has been
reported by protein transduction of Oct4, Sox2, Klf4, and c-Myc
fused with a CPP in combination with a histone deacetylase
inhibitor, valproic acid [158]. However, human-iPS cells have0 vol. 53 j 738–751 745
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been generated by exposing human neonatal ﬁbroblasts to cell
extracts from HEK293 cell lines that expressed high levels of
the four reprogramming factors in the absence of additional
chemicals [60] (Fig. 1). In contrast to the prior study, the efﬁ-
ciency of iPS cell generation is low in the protein transduction
approach and requires further optimization. The application of
small molecules to increase reprogramming efﬁciency may also
facilitate reprogramming with a virus-free approach [52,115]
(Fig. 1). Using a high-throughput screening of exogenous factors
and small molecules, Jaenisch and colleagues identiﬁed a small
molecule, kenpaullone, that can replace Klf4 in the formation of
mouse iPS cells [76,113,67]. The screening of small molecules
that can contribute to the generation of iPS cells may eventually
lead to the development of fully chemically deﬁned conditions
for the production of iPS cells.
The application of protein transduction and small molecular
approaches possibly represent a signiﬁcant advance in generating
iPS cells, effectively eliminating any risk of modifying the target
cell genome by exogenous genetic sequences which have been
associated with all previous iPS cell methods, and consequently
offer a method for generating safer human-iPS cells. Moreover,
removal of the reprogramming vector has increased the similar-
ity of iPS cells to ES cells [120] thus markedly improving their
developmental potential and differentiation capacity [121].
Although promising, the efﬁciency of iPS cell generation is low
in both methods and requires further optimization. In particular,
the concentrations of the individual factors need to be calibrated
to approximate normal endogenous levels. Additionally, strate-
gies for exploiting endogenous gene expression in certain cell
types has also allowed for easier reprogramming and/or fewer
required exogenous genes [60,61,115].
Target cell puriﬁcation before clinical application
Assuming that ES and iPS cell-derived progenitors of mature cells
or the ﬁnal differentiated cells used for transplantation are suc-
cessfully derived in a quantity and quality appropriate for trans-
plantation; it will still be necessary to remove undifferentiated
iPS cells and other cell types that have the potential to form
tumors in vivo (for review see [62,64,73]).
The most direct strategy is to purify cells using ﬂuorescence
activated cell sorting (FACS). The application of this method relies
on the expression of a cell-type-speciﬁc reporter (e.g. promoter
driving expression of a ﬂuorescent protein) or by cell-surface
molecules recognized by antibodies such as the anti-cell mem-
brane hepatocyte marker, ASGPR [9]. The cells could be sorted
via progenitor cell speciﬁc markers (positive sorting) or stem cell
speciﬁc markers (negative sorting). Consequently, it is highly
desirable to identify suitable markers for the puriﬁcation of
human cells for clinical applications. In addition, antibody pro-
duction and transfection reagents will require standardization
to comply with FDA regulations. The cell-sorting procedures will
also need to be carried out with dedicated ﬂow cytometers that
are free from exposure to xenobiotics. Introduction of a stem cell
speciﬁc suicide gene to eliminate stem cells is another strategy to
purify a given cell type [62,64,73].
Increasing the efﬁciency of reprogramming
Within three years of publication of the ﬁrst iPS cells in 2006
[134], much progress has been made towards their generation746 Journal of Hepatology 201and applications. However, since the generation of the ﬁrst iPS
cells, attempts have been made to increase the efﬁciency of
fully-reprogrammed iPS cells for therapeutic applications.
These include the application of various sets of reprogram-
ming factors [70,77], reprogramming different somatic cell types
[2,31,140], application of chemicals/small molecules to increase
efﬁciency, replacing reprogramming factors [51,88,114], and the
use of hypoxia conditions [65]. Nevertheless, the generation of
iPS cells has, so far, been an inefﬁcient process (<2%) resulting
in a heterogeneous population of cells which makes the identiﬁ-
cation of fully-reprogrammed iPS cells challenging. More
recently, several groups have shown that the inactivation of
p53 remarkably increased the efﬁciency of iPS cellular generation
[48,58,78,140]. However, the inactivation of p53 may result in
low quality iPS cells, thus causing genomic abnormalities. Given
the rapid advancements within the iPS cell ﬁeld, it is most likely
that highly efﬁcient, safe iPS cells will be routinely generated in
the near future.
Patient-speciﬁc iPS cells: custom- versus ready-made iPS cells
A potential beneﬁt would be the ability to generate patient-spe-
ciﬁc iPS cells that can be transplanted without the concern of
rejection or the need for immunosuppressive drugs. However,
custom-made iPS cells may not be available any time soon. Even
if the capability to generate safe iPS cells becomes available, the
generation and expansion of iPS cells would take a couple of
months. Moreover, several more months will be needed to differ-
entiate iPS cells into the required cell types and to subsequently
expand them. Subsequently, several steps should be taken to
ensure the cells are safe for transplantation and do not form
tumors.
All in all, the generation of custom-made iPS cells will be a
very costly process and therefore only available to a subset of
the population. Additionally the process is presently too slow
for the treatment of disorders such as spinal cord injuries which
would need prompt treatment. Therefore, ready-made iPS cells
have been proposed as a solution. Japanese scientists are prepar-
ing a national library of therapy-ready iPS cell lines. It has been
estimated that 50 well-chosen cell lines could provide close
immunological matches for 90% of the Japanese population.
Therefore, patients who require urgent treatment could use
the best immunological match, whereas people with chronic dis-
orders might chose to have an iPS cell line that is patient speciﬁc,
provided they could afford it [23].
Generation of fully-reprogrammed iPS cells
It has been shown that some of the iPS clones are only partially
reprogrammed into an ES cell state [18,74]. Shutdown of the
exogenously expressed transcription factors which can be
detected early during reprogramming is one of the most speciﬁc
single markers of reprogramming success. Lowry et al. have
reported in their research, that some of the human iPS clones
generated were only partially reprogrammed to an ES cell state
whereas other clones appeared faithfully reprogrammed, as mea-
sured by their gene expression program and their inability to
form embryoid bodies [74]. Recently, Chen et al. identiﬁed three
distinct colony types which morphologically resembled ES cells
but differed in molecular phenotype and differentiation potential
[18]. They demonstrated that incompletely reprogrammed colo-0 vol. 53 j 738–751
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nies exhibited some features of reprogramming; including down-
regulation of ﬁbroblast markers, expression of pluripotency
markers, changes in the histone modiﬁcation state, formation of
ES cell–like morphology, and the ability to differentiate into ter-
atoma-like tumors. According to Chen et al., SSEA-4, alkaline
phosphatase, hTERT or GDF-3 were insufﬁcient to reliably distin-
guish a fully reprogrammed from a partially reprogrammed state
whereas proviral silencing and expression of TRA-1-60, DNMT3B
and REX1 were suggested as markers to distinguish between fully
and partially reprogrammed iPS cells. Clearly more work should
be undertaken for the rigorous characterization and standardiza-
tion of putative iPS cells [18].
Are iPSCs and ESCs functionally equivalent?
An important outstanding question is the extent to which iPS
cells and ES cells are functionally equivalent. The ﬁrst mouse
iPS cells generated by Yamanaka and Takahashi were similar
to ES cells in the expression of certain ES cell marker genes,
morphology, proliferation, and the formation of teratomas but
these cells failed to produce adult chimeric mice and showed
a different global gene expression [134]. Germline transmission
with mouse iPS cells has been reported [11,157]. However, sev-
eral studies have shown that although human-iPS cells are
quite similar to human ES cells, they are clearly not identical.
Yamanaka and his colleagues reported at least 1267 genes that
display a greater than ﬁve-fold difference in expression levels
in iPS cells when compared with human ES cells [133]. Chan
et al. applied genome-wide methods to compare mouse and
human-iPS cells with ES cells’ subkaryotypic genome alteration,
mRNA, small noncoding RNA expression and histone modiﬁca-
tion proﬁling [18]. They showed that iPS cells represented a
unique type of pluripotent cell as deﬁned by gene expression
and should be considered as a unique subtype of pluripotent
cell.
Recently, it has been shown that removal of the reprogram-
ming vector increased the similarity of iPS cells to ES cells
[120] and markedly improved the developmental potential and
differentiation capacity of iPS cells [121]. The detailed implica-
tions of these differences between iPS cells and ES cells and their
functional role in self-renewal or differentiation are unknown
and need extensive investigation.
Cell source for reprogramming
Another important issue facing researchers concerns the varied
origins of iPS cells which may affect their propensities to differ-
entiate and safety. Certain cell types may be better suited for
complete reprogramming with reduced risks of teratoma forma-
tion [6,85]. It has been assumed that the production of pancre-
atic-b cells and hepatocytes from somatic cell-derived iPS cells
of an endodermal origin, such as gastric epithelial cells or hepa-
tocytes, may be more effective; however, direct evidence for this
assumption is lacking. Recently, Miura et al. have reported that
hepatocyte and gastric epithelial-iPS cell clones fail to generate
neurospheres while ﬁbroblast-iPS cells are efﬁcient neurosphere
producers [85]. Notably, iPS cells derived from epithelial cells
and tissues such as the liver, gastric mucosa [6], and skin [2] have
less retroviral integration than iPS cells derived from ﬁbroblasts.
Those iPS cells which have been derived from mouse hepatocytes
or human keratinocytes show fewer retroviral integration sitesJournal of Hepatology 201when compared with iPS cells derived from ﬁbroblasts. More
recently, the generation of iPS cells from human hepatocytes
was reported [71], however, more studies should examine
whether hepatocytes from these iPS cells offer any advantages
over differentiated cells from human ES cells or from iPS cells
of other origins.Concluding remarks
Human-iPS cells bypass the ethical and immunological con-
cerns associated with human ES cells. They represent an unlim-
ited resource for in vitro modeling and the development of
patient-speciﬁc medicines suitable for treating a number of
deﬁciency states, including human liver disease. That being
said, human iPS cell technology is still in its infancy and a
number of hurdles need to be overcome before cell therapies
become a reality. These include: (i) generation of iPS cells
without viral integration, (ii) increasing the efﬁciency of iPS
cell production such that enough cells will be generated for
iPS cell screening and quality evaluation, (iii) differentiation
of iPS cells into desired cell types that are comparable to their
in vivo counterparts, (iv) isolation of differentiated cells with
sufﬁcient purity, and (v) the proper homing and function of
iPS cells post-transplantation.
Given the rapid pace of developments within the iPS cell ﬁeld,
it is likely that the generation of safe and effective iPS cells for use
in cell therapy will be achieved in the near future.Conﬂict of interest
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